Bioventus Inc. (BVS)
Market Cap | 180.84M |
Revenue (ttm) | 510.62M |
Net Income (ttm) | -283.01M |
Shares Out | 62.79M |
EPS (ttm) | -4.58 |
PE Ratio | n/a |
Forward PE | 64.47 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 13,072 |
Open | 2.94 |
Previous Close | 2.93 |
Day's Range | 2.82 - 3.00 |
52-Week Range | 0.80 - 8.29 |
Beta | 0.33 |
Analysts | Hold |
Price Target | 4.17 (+44.79%) |
Earnings Date | Nov 7, 2023 |
About BVS
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for pr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for BVS stock is "Hold." The 12-month stock price forecast is $4.17, which is an increase of 44.79% from the latest price.
News

Bioventus to Present at the Cantor Global Healthcare Conference
DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief f...

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will ...

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the...

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference
DURHAM, N.C., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief fi...

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023
DURHAM, N.C., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...

Bioventus Completes Divestiture of its Wound Business
DURHAM, N.C., May 23, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully ...

Bioventus Reports First Quarter Financial Results
DURHAM, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the ...

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report f...

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company plans to file...

Bioventus Announces Divestiture of its Wound Business
DURHAM, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a defi...

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report finan...

Bioventus Announces CEO Leadership Change
DURHAM, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that Ken M. Reali has stepped...

Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for th...

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered int...

Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report...

Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fin...

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers an...

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Bioventus Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bioventus Inc. ("Bioventus" o...

BIOVENTUS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss Their Options
NEW YORK , March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ:...

BVS DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Bioventus Inc. Investors with Losses to Secure Counsel Before Important March 13 Deadline in Securities Class Action - BVS
NEW YORK , March 10, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the ...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investor...

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
LOS ANGELES , March 9, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on ...

BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (NASDAQ: BVS)
Did you lose money on investments in Bioventus? If so, please visit Bioventus Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your...

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Bioventus Inc. (BVS) Investors and Encourages Investors to Contact the Firm Before March 13, 2023
NEW YORK--(BUSINESS WIRE)---- $BVS #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Ca...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
NEW YORK , March 3, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and...